IBDEI10Y ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16658,2)
 ;;=^5159102
 ;;^UTILITY(U,$J,358.3,16659,0)
 ;;=D59.12^^61^775^29
 ;;^UTILITY(U,$J,358.3,16659,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16659,1,3,0)
 ;;=3^Autoimmune Hemolytic Anemia,Cold
 ;;^UTILITY(U,$J,358.3,16659,1,4,0)
 ;;=4^D59.12
 ;;^UTILITY(U,$J,358.3,16659,2)
 ;;=^5159103
 ;;^UTILITY(U,$J,358.3,16660,0)
 ;;=D59.13^^61^775^30
 ;;^UTILITY(U,$J,358.3,16660,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16660,1,3,0)
 ;;=3^Autoimmune Hemolytic Anemia,Mixed Type
 ;;^UTILITY(U,$J,358.3,16660,1,4,0)
 ;;=4^D59.13
 ;;^UTILITY(U,$J,358.3,16660,2)
 ;;=^5159104
 ;;^UTILITY(U,$J,358.3,16661,0)
 ;;=D59.19^^61^775^31
 ;;^UTILITY(U,$J,358.3,16661,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16661,1,3,0)
 ;;=3^Autoimmune Hemolytic Anemia,Other
 ;;^UTILITY(U,$J,358.3,16661,1,4,0)
 ;;=4^D59.19
 ;;^UTILITY(U,$J,358.3,16661,2)
 ;;=^5159105
 ;;^UTILITY(U,$J,358.3,16662,0)
 ;;=D57.20^^61^775^201
 ;;^UTILITY(U,$J,358.3,16662,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16662,1,3,0)
 ;;=3^Sickle-Cell/Hb-C Disease w/o Crisis
 ;;^UTILITY(U,$J,358.3,16662,1,4,0)
 ;;=4^D57.20
 ;;^UTILITY(U,$J,358.3,16662,2)
 ;;=^330080
 ;;^UTILITY(U,$J,358.3,16663,0)
 ;;=D57.211^^61^775^196
 ;;^UTILITY(U,$J,358.3,16663,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16663,1,3,0)
 ;;=3^Sickle-Cell/Hb-C Disease w/ Acute Chest Syndrome
 ;;^UTILITY(U,$J,358.3,16663,1,4,0)
 ;;=4^D57.211
 ;;^UTILITY(U,$J,358.3,16663,2)
 ;;=^5002310
 ;;^UTILITY(U,$J,358.3,16664,0)
 ;;=D57.212^^61^775^200
 ;;^UTILITY(U,$J,358.3,16664,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16664,1,3,0)
 ;;=3^Sickle-Cell/Hb-C Disease w/ Splenic Sequestration
 ;;^UTILITY(U,$J,358.3,16664,1,4,0)
 ;;=4^D57.212
 ;;^UTILITY(U,$J,358.3,16664,2)
 ;;=^5002311
 ;;^UTILITY(U,$J,358.3,16665,0)
 ;;=D57.213^^61^775^197
 ;;^UTILITY(U,$J,358.3,16665,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16665,1,3,0)
 ;;=3^Sickle-Cell/Hb-C Disease w/ Cerebral Vascular Involvement
 ;;^UTILITY(U,$J,358.3,16665,1,4,0)
 ;;=4^D57.213
 ;;^UTILITY(U,$J,358.3,16665,2)
 ;;=^5159080
 ;;^UTILITY(U,$J,358.3,16666,0)
 ;;=D57.218^^61^775^198
 ;;^UTILITY(U,$J,358.3,16666,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16666,1,3,0)
 ;;=3^Sickle-Cell/Hb-C Disease w/ Crisis w/ Oth Complication
 ;;^UTILITY(U,$J,358.3,16666,1,4,0)
 ;;=4^D57.218
 ;;^UTILITY(U,$J,358.3,16666,2)
 ;;=^5159081
 ;;^UTILITY(U,$J,358.3,16667,0)
 ;;=D57.219^^61^775^199
 ;;^UTILITY(U,$J,358.3,16667,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16667,1,3,0)
 ;;=3^Sickle-Cell/Hb-C Disease w/ Crisis,Unspec
 ;;^UTILITY(U,$J,358.3,16667,1,4,0)
 ;;=4^D57.219
 ;;^UTILITY(U,$J,358.3,16667,2)
 ;;=^5002312
 ;;^UTILITY(U,$J,358.3,16668,0)
 ;;=D57.3^^61^775^195
 ;;^UTILITY(U,$J,358.3,16668,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16668,1,3,0)
 ;;=3^Sickle-Cell Trait
 ;;^UTILITY(U,$J,358.3,16668,1,4,0)
 ;;=4^D57.3
 ;;^UTILITY(U,$J,358.3,16668,2)
 ;;=^5002313
 ;;^UTILITY(U,$J,358.3,16669,0)
 ;;=D57.40^^61^775^192
 ;;^UTILITY(U,$J,358.3,16669,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16669,1,3,0)
 ;;=3^Sickle-Cell Thalassemia w/o Crisis
 ;;^UTILITY(U,$J,358.3,16669,1,4,0)
 ;;=4^D57.40
 ;;^UTILITY(U,$J,358.3,16669,2)
 ;;=^329908
 ;;^UTILITY(U,$J,358.3,16670,0)
 ;;=D57.411^^61^775^193
 ;;^UTILITY(U,$J,358.3,16670,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16670,1,3,0)
 ;;=3^Sickle-Cell Thalassemia,Unspec w/ Acute Chest Syndrome
